FOXM1 and PD-L1 in CDK4/6-MEK Resistance in Nerve Tumors
October 1, 2024
“We suggest that future therapeutic strategies targeting the oncogenic network of CDK4/6, MEK, PD-L1, and FOXM1 represent exciting future treatment options for MPNST patients.” BUFFALO, NY- October 1, 2024 –… read more